openPR Logo
Press release

Hear from Sanofi and Merck at SMi’s Injectable Drug Delivery 2019

02-05-2019 10:26 AM CET | Health & Medicine

Press release from: SMi Group

Hear from Sanofi and Merck at SMi’s Injectable Drug Delivery

Hear from Sanofi as they will be presenting the Keynote Address: Overcoming the challenges in development of injectable protein formulations on day one by Vasco Filipe, Senior research scientist - Formulation Development at the 2nd annual Injectable Drug Delivery conference taking place on the 15-16 May 2019, in London, UK.

Below is a summary of Vasco Filipe presentation:
Opening Keynote Address: Overcoming the challenges in development of injectable protein formulations - Day 1 | 09:10
- High viscosity that exceeds the capabilities of current manufacturing practices or available parenteral delivery methods
- High concentration leading to stability and aggregation concerns and the associated material required for a robust development strategy
- High volume biologic challenges and strategies to overcome them
- Viscosity reducing excipients

Vasco Filipe is a Biological Engineer and obtained a Ph.D. degree in Pharmaceutical Sciences from the Utrecht University (The Netherlands) in 2011. His thesis focused on the physicochemical characteristics, stability in biological fluids and immunogenicity of monoclonal antibody aggregates. After a post-doc in 2012 on a similar topic, he then joined Adocia in 2013 (Lyon, France), where he worked as the Project Leader for all monoclonal antibodies’ collaborations. In 2015 he joined Sanofi (Paris, France), where he now works as a Section Head of Formulation and Process Development in the department of Biologics Drug Product Development.
----------------------------------
Quentin Le Masne, Head of Engineering team - Electro-Medical, Drug Delivery Devices, Merck will be presenting on: Development of electronic auto-injectors - from concept to manufacture on day two at 11.00am

Below is a summary of Quentin Le Masne presentation:
- Overview of the development process – the do’s and don’ts
- The challenges and learnings of electronic and connected drug delivery devices
- User experience and patient-centric design: what do patients really want from electronic auto-injectors?

Quentin Le Masne holds a master’s degree in Engineering for Ecole Centrale de Paris and a PhD in Physics from Paris University. He has worked in numerous positions in the field of medical devices, from In-Vitro Diagnostic to Drug Delivery Devices, restlessly bringing highly innovative ideas from lab to market. His work focuses on the management of engineering teams with diverse expertise like electronic, mechanics, human factors, physics, fluidics, and manufacturing to bring new products in the doctor’s and patient’s hands. He is now in charge of the development of novel electronic drug delivery devices for Merck.

For those looking to attend there is currently a £300 early-bird saving, ending February 28th.

Further information is available at: www.injectable-drug-delivery.com/openpr2

SMi presents the 2nd Annual Conference:
Injectable Drug Delivery
Date: 165h – 16th May 2019
Workshops: 14th May 21019
Location: Copthorne Tara Hotel Kensington, London
Website: www.injectable-drug-delivery.com/openpr2

---ENDS---

Contact Information:
For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6048 / Email: hsidhu@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Road

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hear from Sanofi and Merck at SMi’s Injectable Drug Delivery 2019 here

News-ID: 1560157 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug